Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) ended Friday session in green amid volatile trading. The shares closed up +0.25 points or 2.96% at $8.69 with 4.86 million shares getting traded. Post opening the session at $8.71, the shares hit an intraday low of $8.54 and an intraday high of $9.19 and the price vacillated in this range throughout the day. The company has a market cap of $1.24 billion and the numbers of outstanding shares have been calculated to be 136.68 million shares.
Achillion Pharmaceuticals, Inc. (ACHN) on Sept. 23, 2016 announced that updated interim results were presented in an ePoster describing a phase 2 study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies (Janssen) at the European Association for the Study of the Liver (EASL) Special Conference in Paris, France.
These results, updated to include expanded safety and efficacy data, were presented in the ePoster entitled “Short duration treatment with AL-335 and odalasvir (ODV), with or without simeprevir (SMV), in treatment-naïve patients with hepatitis C virus (HCV) genotype (GT) 1 infection.” It reports that 100 percent of patients receiving treatment for as short as six weeks with a triple combination of once-daily (QD) AL-335 800mg and simeprevir (SMV) 75mg with 50mg every other day (QOD) of ODV achieved a sustained viral response 12 weeks after the completion of treatment (SVR12).
“Odalasvir has continued to show that it has the potential to shorten the treatment duration to as little as six weeks in combination with other direct acting antivirals for the treatment of HCV,” commented Dr. Milind Deshpande, president and chief executive officer of Achillion. “We now look forward to seeing confirmation of these impressive data in Janssen’s global development program.”
Shares of Johnson & Johnson (NYSE:JNJ) ended Friday session in red amid volatile trading. The shares closed down -0.65 points or -0.54% at $118.81 with 4.77 million shares getting traded. Post opening the session at $119.41, the shares hit an intraday low of $118.71 and an intraday high of $119.60 and the price vacillated in this range throughout the day. The company has a market cap of $324.78 billion and the numbers of outstanding shares have been calculated to be 2.74 billion shares.
Johnson & Johnson (JNJ) announced that it will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 18th, to review third-quarter results. Dominic Caruso, Executive Vice President, Chief Financial Officer, Joaquin Duato, Executive Vice President, Worldwide Chairman, Pharmaceuticals, Dr. William Hait, MD. PhD, Global Head Janssen Research & Development, LLC, and Joseph J. Wolk, Vice President, Investor Relations, will host the call.
Investors and other interested parties may access the conference call in the following ways:
The webcast is accessible at Johnson & Johnson’s website: www.investor.jnj.com. A webcast and podcast replay will be available approximately one hour after the conference call concludes.
By telephone: for both “listen-only” participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261.
A replay of the conference call will be available until approximately 12:00 a.m. on October 25, 2016. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13645877.
Presentation materials will be available on www.investor.jnj.com.
The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call.